Top 10 ibab.ac.in Competitors

biotecnika.org

Scientists Stunned as Google AI Discovers New Cancer Drug with it's Gemma model and validates a new drug combination for cancer treatment.

mcb.iisc.ac.in

mcb - department of microbiology and cell biology

csc.iitd.ac.in

csc, iitd

cbn.rutgers.edu

Department of Cell Biology and Neuroscience

kaher.edu.in

KAHER stands as a distinguished institution renowned for its commitment to excellence in health science education and pioneering research.

iba-worldwide.com

Read the entire full year 2024 results press release in the pdf EN or FR in the right column of this page Louvain-la-Neuve, Belgium, 20 March 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2024 financial year. Record-high revenue and return to profitability in 2024 driven by well-executed backlog conversionNet sales rose 7% to €498.2 million[1], with Other Accelerators increasing by 18%Gross margin improvement to 33.3% vs. 28.8% in 2023, driven by higher share of Other Accelerators and margin improvement in Proton TherapyREBIT at €17.3 million, up 170% (FY 2023: €6.4 million) mostly from well-executed backlog conversion, especially in Other Accelerators (+€11 million REBIT YoY), including continued investments in future growth and R&D innovationNet result of €9.3 million compared to a net loss of €9.1 million in 2023Sustained growth in equipment order intake (+11% YoY) with a strong year from Other Accelerators (+43%). Proton Therapy order intake gained momentum in Q4 (5 accelerator systems sold in 2024)  Backlog stable at all-time high with €1.5 billion, providing significant visibility for the future Strong balance sheet reflected in €33.5 million net cash position at year-end and access to €60 million undrawn credit lines Continued investment in future value creation, in particular PanTera securing an over-subscribed Series A round valuing the company at approximately €280 million post money. This funding round aims to accelerate global Actinium-225 production New segment reporting following updated organization structure in three focused entities: IBA Clinical, IBA Technologies and IBA Corporate. New reporting will be applied as of 2025 with 2024 pro-forma available in Section III CFO transition: Henri de Romrée, Deputy CEO, appointed interim CFO following the departure of Soumya Chandramouli Updated mid-term outlook: 2024-28 revenue CAGR of 5-7% with c.10% REBIT marg

bioconacademy.com

Admissions are open for the Biocon KGI Certificate Program in Biosciences, offering industry-oriented learning, and strong placement support for biotechnology and pharmacy graduates.